Barcode Nanotech
Target-specific nanoparticles for next generation RNA therapies
Company Overview
Snapshot
Founded in March 2017 by Ronen Eavri, Avi Schroeder, and Annie Sabbah, Barcode Nanotech operates with 1–10 employees. The company has raised $7.6M across five funding rounds from four investors. In August 2022, NGT HealthCare II participated in a Seed funding round.
Business overview
Barcode Nanotech is a Health Tech & Life Sciences company specializing in developing targeted delivery vehicles for next-generation RNA/DNA therapeutics. The company's core technology involves proprietary Lipid Nanoparticles (LNPs) designed to selectively reach target cells and tissues, protecting RNA molecules from degradation. Barcode Nanotech utilizes an AI-based platform for designing these LNPs and a high-throughput in vivo screening platform for rapid optimization. It serves markets in Asia, Northern Europe, Americas, Europe, and Western Europe, focusing on selective indications such as hard-to-treat cancers, metabolic diseases, and fibrosis.
Strategic signal
In July 2026, Galmed announced a breakthrough development in collaboration with Barcode Nanotech, creating a novel LNP cardiac-targeted formulation of its SCD1 inhibitor, Aramchol. This partnership demonstrates Barcode Nanotech's capability in developing specialized delivery systems for therapeutic compounds, signaling strong potential for future collaborations and advancements in targeted drug delivery.
Log in to access full profile ›Company Intelligence Q&A
- What is Barcode Nanotech's primary focus?
- Barcode Nanotech focuses on developing target-specific nanoparticles for next-generation RNA therapies, addressing the critical need for precise and safe delivery of RNA/DNA therapeutics to target organs and cells.
- When was Barcode Nanotech founded and by whom?
- Barcode Nanotech was founded in March 2017 by Ronen Eavri, Avi Schroeder, and Annie Sabbah.
- What was a significant recent development for Barcode Nanotech?
- In July 2026, Galmed announced the breakthrough development of a novel LNP cardiac-targeted formulation of its SCD1 inhibitor, Aramchol, in collaboration with Barcode Nanotech.
- Which investors participated in Barcode Nanotech's funding rounds?
- Barcode Nanotech has received funding from investors including NGT HealthCare II and OurCrowd.
- What kind of technology does Barcode Nanotech utilize for its products?
- Barcode Nanotech generates proprietary lipid nanoparticles (LNPs) using an AI-based platform for design and a high-throughput in vivo screening platform for rapid testing and optimization.